
Activity-Based Proteomics – Protein and Ligand Discovery on a Global Scale


Benjamin F. Cravatt Department of Molecular Medicine The Skaggs Institute for Chemical Biology The Scripps Research Institute

Current State of Understanding of Biochemical Pathways in Mammalian Cells



Cell metabolism (perception)

Candidate Profiling Strategies for Mapping Biochemical Pathways



Genomics Proteomics Chemical technologies

Overview

 Activity-based Protein Profiling (ABPP) – Original Concepts and Technology

• Extending ABPP – Mapping the Ligandability of the Human Proteome


Overview

Activity-based Protein Profiling (ABPP) – Original Concepts and Technology

• Extending ABPP – Mapping the Ligandability of the Human Proteome

Chemical Probes for Activity-Based Profiling

- Activity-based probes should:
- 1) Bind and label many enzymes in proteomes
- 2) Labeling should be activity-dependent
- 3) Possess a reporter tag for detection/identification



Representative Enzyme Classes Addressed by Activity-Based Protein Profiling (ABPP)


- Serine hydrolases (Cravatt et al)
- Cysteine proteases (Bogyo et al)
- Histone deacetylases (Cravatt et al)
- Kinases, Phosphatases (Activx, Taunton, Zhang)
- Metalloproteases (Cravatt et al, Yao et al)
- Glycosidases (Overkleeft, et al)
- Cytochrome P450s (Cravatt et al)

Representative Enzyme Classes Addressed by Activity-Based Protein Profiling (ABPP)


- Serine hydrolases (Cravatt et al)
- Cysteine proteases (Bogyo et al)
- Histone deacetylases (Cravatt et al)
- Kinases, Phosphatases (Activx, Taunton, Zhang)
- Metalloproteases (Cravatt et al, Yao et al)
- Aspartyl proteases (Li, et al)
- Cytochrome P450s (Cravatt et al)

Serine Hydrolases – A Large and Diverse Enzyme Class

- ~1-2% of all eukaryotic and prokaryotic proteomes
 - proteases, lipases, esterases, transacylases, amidases





Fluorophosphonates as General Activity-Based Profiling Probes for Serine Hydrolases




Fluorophore - detection (in-gel) Biotin - enrichment

ABPP Coverage of Mammalian Serine Hydrolases






Inhibitor Discovery by Competitive Activity-Based Protein Profiling




Advantages:

- No enzyme purification required
- No substrate assay required
- Evaluates both inhibitor potency AND selectivity

Systematic Discovery of Serine Hydrolase Inhibitors by Competitive ABPP



Toward a Complete Pharmacology For the Serine Hydrolase Superfamily



Integrating ABPP with Human Genetics to Map Orphan Disease Mechanisms



ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC

Jacqueline L. Blankman^{a,b}, Jonathan Z. Long^{a,b}, Sunia A. Trauger^c, Gary Siuzdak^c, and Benjamin F. Cravatt^{a,b,1}

^aThe Skaggs Institute for Chemical Biology and Departments of ^bChemical Physiology and ^cMolecular Biology, The Scripps Research Institute, La Jolla, CA 92037


The hereditary spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase

Jordon M. Inloes^{a,b,1}, Ku-Lung Hsu^{a,b,1}, Melissa M. Dix^{a,b}, Andreu Viader^{a,b}, Kim Masuda^{a,b}, Thais Takei^{a,b}, Malcolm R. Wood^c, and Benjamin F. Cravatt^{a,b,2}

^aThe Skaggs Institute for Chemical Biology and Departments of ^bChemical Physiology and ^cMolecular Biology, The Scripps Research Institute, La Jolla, CA 92037

Excavating Cases of Convergent/Parallel Evolution of Unpredecented Hydrolase Activities by ABPP

If FP reactivity marks hydrolase activity...



AIG1 (and ADTRP) are Multi-Pass Transmembrane **Proteins of Poorly Characterized Function**

H. sapiens AIG1

- M. musculus AIG1
- D. rerio AIG1
- gambiae AGAP008626-PA Α.
- S. cerevisiae YHR140W
- sapiens ADTRP Η.

H. sapiens AIG1

M. musculus AIG1

rerio AIG1

D.

Α.

Η.

rerio LOC100537455

S. cerevisiae YHR140W

D. rerio LOC100537455

sapiens ADTRP


1 --MALVPCQ---VLRMAILLSYCSILCNYKAIEMPSHQT----YGGSWKFL T FIDLVIQAVFFGICVL --MALVPCQ---VLRVAILLSYCSILCNYKAIEMPSHQT----YGGSWKFL **T** FIDLVIQAVFFGICVL [51]RKMALIPSO---ILRVAILLSYFSILCNYKAIDMPAHOT----YGGSWKFL **T** FIDLVIOAVFFGVCVL [14]VYGALRTLM---HFIVAVOFSY-GIYYDFTYVHFPPGMLRPGGEFGGKLKYL VWDAILOAVYFTICLL т MMSCLVPTRFTLTLNTACLLTSTWGFVRATSVVLPPSLSK----AGHKOFL т IISIIATIINNAVNIS T LLNLLLQTIFYGVTCL ---MTKTST---CIYHFLVLSWYTFLNYYISQEGKDEVKPKILANGARWKYM [10]TASMAGVMK---TFCHIAAFSWYAFIIQCIYAKDVSDLPSGIFVYGGPWKYL

*

60 TDLSSLLTRGSGNOEOEROLKKLISLRDWMLAVLAFPVGVFVVAVFWIIYAYDREMIY---PKLLDNFIPG TDLSSLLTRGSGNQEQERQLRKLISLRDWTLAVLAFPVGVFVVAVFWTIYAYDREMIY---PRLLDNFIPG TDLSSLLTKGSASMEQERQLRKLIGLRDWMMAVLAFPVGVFVVTMFWTLYLYDRDLIY---PRLLDNFIPQ gambiae AGAP008626-PA NDFIGT----NEVAPKRMPLIRKLKDYMLAAFAFPVALNVGVTFWTLMAIDRELVF---PKALDAVFPG NYYIOR----NNKMNLETKKKSDFISRHVTLPVSLVLESIVATVYWPLRLFFVNLIMHGVESTAKTPFPM DDVLKR-TKGG-----KDIKFLTAFRDLLFTTLAFPVSTFVFLAFWILFLYNRDLIY---PKVLDTVIPV ND-LOP-VGKG-----SKMSLLCLCKDLLFSVFVFPVGMFVVLLFWLIFAYDRQLVY---PASIDNFFPP

* * * 128 WLNHGM H sapiens AIG1 TTVLPFILIEMRTSHHQYP---SRSSGLTAICTFSVGYILWVCWVHHVTGMWVYPF-LEHIG Η. musculus AIG1 TTVLPFILIEMRTSHHOYP---SRSSGLAAICTFSVGYILWVCWIHHVTGMWVYPF-LEHIG Μ. WLNHGM H TTVLPFIIIEMRTTHHRYP---SRPCGLLAVCAFAVGYVVWMCWVHSMTGVWVYPL-LEHIG rerio AIG1 WLNHGM H D. gambiae AGAP008626-PA TNIVIFMVIEICTSFRQYP---SRKAGLTGLGIFMASYLGWLHVVRHFGGIWVYPV-LDVLN WLNHVM H Α. cerevisiae YHR140W TVDMAI H LYPILYLLADHYLSGSGTKFKLSNKHAWLIVTSLAFSYFOYLAFLIDAGOGOAYPYPFLDVN S. sapiens ADTRP WLNHAM H TFIFPITLAEVVLRPHSYP---SKKTGLTLLAAASIAYISRILWLYFETGTWVYPV-FAKLS Η. D. rerio LOC100537455 WLNHAM H TVVLPILFGEILLEPHVFP---KTKNGLAALGVVGLAYLGWVIWVYCTVGIWVYPL-LGLFS

AIG1 (and ADTRP) are Founding Members of a New Class of Transmembrane Thr-Hydrolases




FAHFAs – A Class of Lipid Transmitters that Regulate Metabolic and Inflammatory Processes

Cell


Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory Effects

Mark M. Yore,^{1,5} Ismail Syed,^{1,5} Pedro M. Moraes-Vieira,¹ Tejia Zhang,^{3,7} Mark A. Herman,¹ Edwin A. Homan,³ Rajesh T. Patel,² Jennifer Lee,¹ Shili Chen,^{3,7} Odile D. Peroni,¹ Abha S. Dhaneshwar,¹ Ann Hammarstedt,⁴ Ulf Smith,⁴ Timothy E. McGraw,² Alan Saghatelian,^{3,6,7,*} and Barbara B. Kahn^{1,6,*}


318 Cell 159, 318–332, October 9, 2014 ©2014 Elsevier Inc.



AIG1 Inhibitors Discovered by ABPP



AIG1 Regulates FAHFA Metabolism in Human Cells



Conclusions and Future Directions

- AIG1 and ADTRP appear to represent a mechanistically unprecedented class of hydrolases
 - transmembrane Thr hydrolases
- Why such an unusual mechanism?

– FAHFAs are unusual substrates

• Do AIG1 and ADTRP regulate FAHFAs in vivo?

- potential relevance for treating metabolic disorders


Chemical proteomics can assign functions to proteins that defy sequence- and structure-based predictions

Overview


• Activity-based Protein Profiling (ABPP) – Original Concepts and Technology

• Extending ABPP – Mapping the Ligandability of the Human Proteome


Challenges and Opportunities for Design of Covalent Ligands that Target Cysteine Residues




Proteome-Wide Covalent Ligand Discovery



Proteome-Wide Covalent Ligand Discovery



Proteome-Wide Covalent Ligand Discovery Accesses New (Un)Druggable Space



Initiator Caspases (CASP8 & CASP10) - Human Genetic Evidence for Key Roles in Immunology

letters to nature

Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency

Hyung J. Chun*†, Lixin Zheng*†, Manzoor Ahmad*†, Jin Wang*‡, Christina K. Speirs*, Richard M. Siegel*‡, Janet K. Dale§ Jennifer Puck||, Joie Davis||, Craig G. Hall¶, Suzanne Skoda-Smith¶ T. Prescott Atkinson¶, Stephen E. Straus§ & Michael J. Lenardo*


NATURE | VOL 419 | 26 SEPTEMBER 2002 | www.nature.com/nature

Cell, Vol. 98, 47-58, July 9, 1999, Copyright ©1999 by Cell Press

Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II

Jin Wang,* Lixin Zheng,* Adrian Lobito,* Francis Ka-Ming Chan,* Janet Dale,[†] Michael Sneller,[‡] Xu Yao,[∥] Jennifer M. Puck,[§] Stephen E. Straus,[†] and Michael J. Lenardo*#

Respective Roles of Caspase-8 and -10 in Human T Cell Biology



Initiator Caspases (CASP8 & CASP10) - Human Genetic Evidence for Key Roles in Immunology

letters to nature

Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency

Hyung J. Chun*†, Lixin Zheng*†, Manzoor Ahmad*†, Jin Wang*‡, Christina K. Speirs*, Richard M. Siegel*‡, Janet K. Dale§ Jennifer Puck||, Joie Davis||, Craig G. Hall¶, Suzanne Skoda-Smith¶ T. Prescott Atkinson¶, Stephen E. Straus§ & Michael J. Lenardo*

NATURE | VOL 419 | 26 SEPTEMBER 2002 | www.nature.com/nature


PROBLEM: selective and drug-like inhibitors of caspases have proven difficult to generate

Cell, Vol. 98, 47-58, July 9, 1999, Copyright ©1999 by Cell Press


Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II

Jin Wang,* Lixin Zheng,* Adrian Lobito,* Francis Ka-Ming Chan,* Janet Dale,[†] Michael Sneller,[‡] Xu Yao,[∥] Jennifer M. Puck,[§] Stephen E. Straus,[†] and Michael J. Lenardo*#


Covalent Ligands that Target the Pro (Inactive) Forms of Caspases



Dual Pro-Caspase-8/10 and Selective Pro- Caspase-8 Ligands



FAS Ligand-Mediated Apoptosis in Human T Cells Requires Both Caspase-8 and -10



Conclusions and Future Directions

- Chemical proteomics reveals a rich content of ligandable cysteines in the human proteome
- Combining cysteine ligandablity maps with human genetics identifies:
 - Novel way to drug initiator caspases important for human immunology

- Sites of action for the immunosuppressive drug Tecfidera (dimethylfumarate) – Blewett *et al.* 2016

- Future Directions:
 - Ligand optimization
 - Extension to other (non)-nucleophilic residues

Conclusions and Future Directions

• Chemical proteomics reveals a rich content of ligandable cysteines in the human proteome

• Combining cysteine ligandablity maps with human genetics identifies:


- Novel way to drug initiator caspases important for human immunology

- Sites of action for the immunosuppressive drug Tecfidera (dimethylfumarate) – Blewett *et al.* 2016


- Future Directions:
 - Ligand optimization

- Extension to other (non)-nucleophilic residues

Proteome-Wide Non-Covalent Ligand Discovery with Fully Functionalized Fragment Probes (Chris Parker)




Proteome-Wide Non-Covalent Ligand Discovery with Fully Functionalized Fragment Probes




11

HEK293T (soluble)


Fragment-Based Ligand Discovery in Living Cells




Discovery of an Inhibitor of the Mitochondrial Acylcarnitine Transporter SLC25A20




Proteome-Wide Non-Covalent Ligand Discovery with Fully Functionalized Fragment Probes






Phenotypic Screening w/ Fragment Library Identifies Novel Ligand-Protein Pathway that Regulates Adipogenesis



Phenotypic Screening w/ Fragment Library Identifies Novel Ligand-Protein Pathway that Regulates Adipogenesis



+ hPGRMC2

Conclusions and Future Directions

- Chemical proteomics enables fragment-based ligand discovery directly in living cells
- Applications include:
 - Discovery of first-in-class ligands for human proteins
 - Integrated phenotypic screening and target ID
- Future Directions:
 - Ligand optimization for "undruggable" proteins
 - Improved site-of-labeling coverage
 - Additional phenotypic screens

Acknowledgments

Cravatt lab members

- Keriann Backus
- Liron Bar-Peled
- Alice Chen
- Megan Blewett
- Armand Cognetta
- Bruno Correia
- Melissa Dix
- Stephan Hacker
- Jordon Inloes
- Taka Ichu
- Mike Lazaer

- Kenneth Lum
- Alice Chen
- Yujia Wang
- Daisuke Ogasawara
- Chris Parker
- Will Parsons
- Esther Kemper
- Kenji Sasaki
- Balyn Zaro
- Radu Suciu
- Katya Vinogradova

Collaborators

- D. Boger (TSRI)
- A. Galmozzi, E. Saez (TSRI)
- John Teijaro (TSRI)
- S. Forli, Art Olson (TSRI)
- M. Lawrence, C. Cavallaro, Johnson, G. Vite (BMS)
- M. Kolar, A. Saghatelian (Salk)
- M. van der Stelt (Leiden)

Funding Support

- NIH (NCI, NIDA, NIGMS)
- BMS

- American Cancer Society
- Pfizer, Abide, Vividion